Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Suginami-ku, Japan Clinical Trials

A listing of Suginami-ku, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (79) clinical trials

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Main ASO Study: This study will compare safety and efficacy of intramuscular transplantation of autologous CD34+ cells (CLBS12) plus standard of care (SOC) pharmacotherapy (cell treatment arm) versus SOC pharmacotherapy alone (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids) (control arm) in subjects with CLI categorized as Rutherford score 4 or ...

Phase

1.79 miles

Learn More »

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.

Phase

1.79 miles

Learn More »

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

This is a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199 monotherapy given as 200 mg/day or 400 mg/day compared with placebo for the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression).

Phase

1.79 miles

Learn More »

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.

Phase

2.56 miles

Learn More »

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess ZPL389 efficacy and safety in subjects with moderate to severe atopic dermatitis.

Phase

2.64 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

The drug being tested in this study is called TAK-906. TAK-906 is being tested to treat people who have symptomatic idiopathic or diabetic gastroparesis. The study will enroll approximately 280 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups (in ...

Phase

3.06 miles

Learn More »

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

In this phase II trial, the investigators evaluate the efficacy and safety of S-588410 containing oncoantigens-derived HLA-A2402-restricted epitope peptides in patients with HLA-A2402 who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Phase

3.18 miles

Learn More »

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, ...

Phase

3.18 miles

Learn More »

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Phase

3.26 miles

Learn More »

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

The patients who complete 16 weeks of treatment in ZPL389 core study will be eligible to participate and patients will be advised to apply TCS and / or TCI concomitantly or intermittently along with once daily oral administration of ZPL389.

Phase

3.26 miles

Learn More »